8-K: Know Labs Announces Positive Clinical Results for Non-Invasive Glycemic Screening Device

Know Labs' study published in Diabetes Technology & Therapeutics demonstrates 93.37% accuracy in classifying glycemic status using a non-invasive radiofrequency sensor.

Summary

• Know Labs has published a peer-reviewed study in Diabetes Technology & Therapeutics Journal showcasing the accuracy of their non-invasive radiofrequency (RF) sensor for glycemic status classification.
• The study involved 31 participants with prediabetes or Type 2 diabetes, using a 75g Oral Glucose Tolerance Test and venous blood draws for comparison.
• The RF sensor and machine learning algorithms correctly classified glycemic status (hyperglycemic, normoglycemic, or hypoglycemic) with 93.37% accuracy compared to venous blood glucose values.
• The model achieved sensitivities of 96.63% for normoglycemic and 85.51% for hyperglycemic classes, with specificities of 84.51% and 96.92%, respectively.
• The company aims to expand the application of this technology beyond continuous glucose monitoring to include a screening device for underserved populations.
• This screening device could potentially reduce diabetes-related hospitalizations and increase access to early diagnosis and intervention globally.

Sentiment

Score: 8

Explanation: The document presents very positive clinical results for a novel technology with significant potential in the diabetes market. The high accuracy and potential for global impact contribute to a strong positive sentiment.

Positives

• The study demonstrates high accuracy (93.37%) for a non-invasive glycemic status classification device.
• The technology has the potential to improve early diagnosis and intervention for diabetes.
• The device could be used to screen underserved populations, increasing access to healthcare.
• The study was published in a reputable peer-reviewed journal, validating the results.
• The technology has the potential to reduce diabetes-related hospitalizations.

Negatives

• More data is needed in the hypoglycemic range to evaluate sensitivity and specificity.
• Further research is required to improve the accuracy and sensitivity of each glycemic status.

Risks

• The technology is still in the proof-of-concept stage and requires further development.
• The company needs to secure strategic partnerships for a Rest of the World (RoW) product.
• The device requires FDA clearance before it can be introduced to the market.
• The company's core focus remains on bringing the first FDA-cleared non-invasive continuous glucose monitor to the marketplace, which may delay the screening device development.

Future Outlook

Know Labs plans to expand the application of its RF technology beyond continuous glucose monitoring to include a screening device, particularly for underserved populations, while maintaining its focus on bringing the first FDA-cleared non-invasive continuous glucose monitor to market. They will seek strategic partners for a Rest of the World (RoW) product.

Management Comments

• Ron Erickson, CEO and Chairman at Know Labs, stated that the proof-of-concept indicates the device's potential to help funnel previously undiagnosed patients more effectively into the healthcare system.
• Chris Somogyi, President, International, will lead efforts to expand the application beyond proof-of-concept.

Industry Context

The announcement is significant in the context of the global diabetes epidemic, where over 500 million people are affected, with a large portion remaining undiagnosed. The development of a non-invasive screening device could address the need for early detection and intervention, potentially reducing healthcare costs and improving patient outcomes. This aligns with the industry's focus on innovative solutions for diabetes management.

Comparison to Industry Standards

• The 93.37% accuracy in classifying glycemic status is a promising result for a non-invasive device, especially when compared to traditional invasive methods.
• Current continuous glucose monitors (CGMs) like those from Dexcom and Abbott require invasive sensors, making Know Labs' non-invasive approach a potential game-changer.
• While other companies are exploring non-invasive glucose monitoring, Know Labs' use of radiofrequency technology and machine learning algorithms is a unique approach.
• The study's focus on classifying glycemic status (hyperglycemic, normoglycemic, or hypoglycemic) is different from the continuous glucose readings provided by CGMs, indicating a potential for a different market segment focused on screening.

Stakeholder Impact

• Shareholders may view the positive clinical results as a positive development for the company.
• Patients with diabetes could benefit from a non-invasive screening device for early detection.
• Healthcare systems could benefit from more efficient resource allocation due to early diagnosis.
• Potential strategic partners may be interested in collaborating on the development of a RoW product.

Next Steps

• Further research is needed to enrich the dataset for categorical screening and improve the accuracy and sensitivity of each glycemic status.
• The company will aim to expand this application beyond proof-of-concept alongside potential strategic partners for a Rest of the World (RoW) product.
• The company will continue its core focus on bringing the first FDA-cleared non-invasive continuous glucose monitor to the marketplace.

Key Dates

Keywords

non-invasive, glucose monitoring, glycemic status, diabetes, radiofrequency, screening device, machine learning, clinical study, sensor, accuracy